Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00106366 · ClinicalTrials.gov registry record · Phase 3

Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes

A Phase 3 study, sponsored by Novo Nordisk A/S.

Completed
Registry status
Phase 3
Development phase
389
Enrollment target

NCT00106366: Completed Phase 3 study, sponsored by Novo Nordisk A/S.

NCT00106366 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 389 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00106366, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.

COMPLETED
Registry status
Phase 3
Development phase
389 participants
Enrollment target

Study Summary

This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patients with Type 2 diabetes.

Interventions

  • DRUG insulin aspart
  • DRUG insulin glargine
  • DRUG insulin detemir

Trial Details

FieldValue
Enrollment Target 389 participants
Start Date 2005-03
Est. Completion 2005-12
Phase Phase 3
Novo Nordisk A/S

431 total trials

What the finished NCT00106366 record still lists

NCT00106366 is an interventional study that assigns participants to a tested intervention. The registered 389 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (50% lower).

The record links to 0 conditions, and to 3 interventions - of which insulin aspart is the first listed.

NCT00106366 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00106366 about?

NCT00106366 is a clinical study titled "Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes". This trial is conducted in the United States of America (USA). The purpose of this study is to determine if the use of insulin detemir in combination with insulin aspart is safe and at least as effective as insulin glargine in combination with insulin aspart for the control of blood glucose in patie...

What is the current status of trial NCT00106366?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 389 participants. The study started on 2005-03. Estimated completion is 2005-12.

What interventions are being tested in trial NCT00106366?

The interventions under investigation include: insulin aspart (DRUG), insulin glargine (DRUG), insulin detemir (DRUG).

Who is sponsoring clinical trial NCT00106366?

This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00106366's enrollment target sits among peer trials

389 972nd of 2000 higher than 1,028 of 2,000 other Phase 3 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05431088 · 389 participants · Phase 2

    A Phase 2/3 Study in Adult and Adolescent Participants With SCD

  • NCT00397111 · 390 participants

    Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders

  • NCT05335928 · 390 participants · Phase 3

    Abatacept in Immune Checkpoint Inhibitor Myocarditis

  • NCT05445960 · 390 participants · NA

    Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00106366, the US trial registry maintained by the National Library of Medicine. NCT00106366 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.